.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
VISUAL II was a multicentre phase 3 randomized, placebo-controlled trial evaluating adalimumab in adults with inactive, non-infectious intermediate, posterior or panuveitis controlled with systemic corticosteroids. Patients were assigned to adalimumab or placebo while prednisone was tapered. Treatment failure occurred significantly less often in the adalimumab group, and time to treatment failure was substantially prolonged. The result supports TNF inhibition as an effective steroid-sparing strategy for patients whose posterior non-infectious uveitis is controlled but remains at risk of recurrence when corticosteroids are reduced. For HCPs, the study illustrates the importance of moving beyond chronic steroid dependence when longer-term immunosuppression is needed. Patient selection must still consider infection screening, tuberculosis risk, vaccination, systemic comorbidity and monitoring. The trial is directly relevant to AIOC's uvea programme and its emphasis on biologic therapies for non-infectious uveitis.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
VISUAL II was a multicentre phase 3 randomized, placebo-controlled trial evaluating adalimumab in adults with inactive, non-infectious intermediate, posterior or panuveitis controlled with systemic corticosteroids. Patients were assigned to adalimumab or placebo while prednisone was tapered. Treatment failure occurred significantly less often in the adalimumab group, and time to treatment failure was substantially prolonged. The result supports TNF inhibition as an effective steroid-sparing strategy for patients whose posterior non-infectious uveitis is controlled but remains at risk of recurrence when corticosteroids are reduced. For HCPs, the study illustrates the importance of moving beyond chronic steroid dependence when longer-term immunosuppression is needed. Patient selection must still consider infection screening, tuberculosis risk, vaccination, systemic comorbidity and monitoring. The trial is directly relevant to AIOC's uvea programme and its emphasis on biologic therapies for non-infectious uveitis.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
